CoChat

Circulating tumor DNA as a potential marker of adjuvant chemotherapy benefit following surgery for localized pancreatic cancer

Open access
Lee, B., Lipton, L., Cohen, J., Tie, J., Javed, A.A., Li, L., Goldstein, D., Burge, M., Cooray, P., Nagrial, A., Tebbutt, N.C., Thomson, B., Nikfarjam, M., Harris, M., Haydon, A., Lawrence, B., Tai, D.W.M., Simons, K., Lennon, A.M., Wolfgang, C.L., Tomasetti, C., Papadopoulos, N., Kinzler, K.W., Vogelstein, B., Gibbs, P. · 2019 · Annals of Oncology
Cited by 215

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

BACKGROUND In early-stage pancreatic cancer there are no currently no biomarkers to guide selection of therapeutic options. This prospective biomarker trial evaluated the feasibility and potential clinical utility of circulating tumour DNA (ctDNA) analysis to inform adjuvant therapy decision making. METHODS Patients considered by the multidisciplinary team to have resectable pancreatic adenocarcinoma were enrolled. Pre- and post-operative samples for ctDNA analysis were collected. PCR-based-SafeSeqS assays were used to identify mutations at codon 12, 13 and 61 of KRAS in the primary pancreatic tumor and to detect ctDNA. Results of ctDNA analysis were correlated with CA19-9, recurrence-free and overall survival. Patient management was per standard of care, blinded to ctDNA data. RESULTS Of 112 patients consented pre-operatively, 81 (72%) underwent resection. KRAS mutations were identified in 91% (38/42) of available tumor samples. Of available plasma samples (N=42), KRAS mutated ctDNA was detected in 62% (23/37) pre-operative and 37% (13/35) post-operative cases. At a median follow-up of 38.4 months, ctDNA detection in the pre- operative setting was associated with inferior recurrence free survival (Hazard Ratio (HR) 4.1; P=0.002) and overall survival (HR 4.1; P=0.015). Detectable ctDNA following curative intent resection was associated with inferior recurrence free survival (HR 5.4; P<0.0001) and overall survival (HR 4.0; P=0.003). Recurrence occurred in 13/13 (100%) patients with detectable ctDNA post-operatively, including in seven that received gemcitabine-based adjuvant chemotherapy. CONCLUSION ctDNA studies in localized pancreatic cancer are challenging, with a substantial number of patients not able to undergo resection, not having sufficient tumor tissue for analysis or not completing per protocol sample collection. ctDNA analysis, pre- and/or post-surgery, is a promising prognostic marker. Studies of ctDNA guided therapy are justified, including of treatment intensification strategies for patients with detectable ctDNA post-operatively who appear at very high risk of recurrence despite gemcitabine-based adjuvant therapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/annonc/mdz200

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 215

Metadata

Authors
Lee, B., Lipton, L., Cohen, J., Tie, J., Javed, A. A., Li, L., Goldstein, D., Burge, M., Cooray, P., Nagrial, A., Tebbutt, N. C., Thomson, B., Nikfarjam, M., Harris, M., Haydon, A., Lawrence, B., Tai, D. W. M., Simons, K., Lennon, A. M., Wolfgang, C. L., Tomasetti, C., Papadopoulos, N., Kinzler, K. W., Vogelstein, B., & Gibbs, P.
Venue
Annals of Oncology
Publisher
Elsevier BV
Published
2019-09
Volume
30
Issue
9
Pages
1472-1478
ISSN
0923-7534 (ISSN-L)
OpenAlex
W2962976163
Cited by
215
References
4
FWCI
9.25
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Circulating tumor DNA as a potential marker of adjuvant chemotherapy benefit following surgery for localized pancreatic cancer. https://app.cochat.ai/papers/10.1093/annonc/mdz200
The paper
Lee, B., Lipton, L., Cohen, J., Tie, J., Javed, A. A., Li, L., Goldstein, D., Burge, M., Cooray, P., Nagrial, A., Tebbutt, N. C., Thomson, B., Nikfarjam, M., Harris, M., Haydon, A., Lawrence, B., Tai, D. W. M., Simons, K., Lennon, A. M., . . . Gibbs, P. (2019). Circulating tumor DNA as a potential marker of adjuvant chemotherapy benefit following surgery for localized pancreatic cancer. Annals of Oncology. https://doi.org/10.1093/annonc/mdz200

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.